Adam Maeder
Stock Analyst at Piper Sandler
(3.93)
# 659
Out of 4,711 analysts
94
Total ratings
52.31%
Success rate
10.58%
Average return
Main Sectors:
Stocks Rated by Adam Maeder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RBOT Vicarious Surgical | Maintains: Neutral | $12 → $11 | $12.00 | -12.50% | 6 | Nov 13, 2024 | |
| NVRO Nevro | Maintains: Underweight | $7 → $6 | $3.79 | +58.31% | 15 | Nov 12, 2024 | |
| INSP Inspire Medical Systems | Reiterates: Overweight | $255 → $260 | $187.77 | +38.47% | 13 | Nov 5, 2024 | |
| NARI Inari Medical | Maintains: Neutral | $50 → $52 | $55.45 | -6.22% | 6 | Oct 29, 2024 | |
| EW Edwards Lifesciences | Maintains: Neutral | $73 → $70 | $74.81 | -6.43% | 12 | Oct 25, 2024 | |
| ISRG Intuitive Surgical | Reiterates: Overweight | $495 → $538 | $524.43 | +2.59% | 17 | Oct 18, 2024 | |
| ABT Abbott Laboratories | Maintains: Overweight | $131 → $133 | $114.23 | +16.43% | 2 | Oct 17, 2024 | |
| NSPR InspireMD | Reiterates: Overweight | $4.5 | $3.00 | +50.00% | 3 | Sep 17, 2024 | |
| M Macy's | Maintains: Hold | $20 → $21 | $16.24 | +29.31% | 2 | May 22, 2024 | |
| STIM Neuronetics | Reiterates: Overweight | $7 → $8 | $1.39 | +475.54% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $8.01 | +149.69% | 8 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $30 | $17.00 | +76.47% | 2 | May 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $2.31 | +116.45% | 2 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $10 → $18 | $8.25 | +118.18% | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $99 | $47.59 | +108.03% | 3 | May 5, 2022 |
Vicarious Surgical
Nov 13, 2024
Maintains: Neutral
Price Target: $12 → $11
Current: $12.00
Upside: -12.50%
Nevro
Nov 12, 2024
Maintains: Underweight
Price Target: $7 → $6
Current: $3.79
Upside: +58.31%
Inspire Medical Systems
Nov 5, 2024
Reiterates: Overweight
Price Target: $255 → $260
Current: $187.77
Upside: +38.47%
Inari Medical
Oct 29, 2024
Maintains: Neutral
Price Target: $50 → $52
Current: $55.45
Upside: -6.22%
Edwards Lifesciences
Oct 25, 2024
Maintains: Neutral
Price Target: $73 → $70
Current: $74.81
Upside: -6.43%
Intuitive Surgical
Oct 18, 2024
Reiterates: Overweight
Price Target: $495 → $538
Current: $524.43
Upside: +2.59%
Abbott Laboratories
Oct 17, 2024
Maintains: Overweight
Price Target: $131 → $133
Current: $114.23
Upside: +16.43%
InspireMD
Sep 17, 2024
Reiterates: Overweight
Price Target: $4.5
Current: $3.00
Upside: +50.00%
Macy's
May 22, 2024
Maintains: Hold
Price Target: $20 → $21
Current: $16.24
Upside: +29.31%
Neuronetics
Mar 6, 2024
Reiterates: Overweight
Price Target: $7 → $8
Current: $1.39
Upside: +475.54%
Mar 6, 2024
Maintains: Overweight
Price Target: $15 → $20
Current: $8.01
Upside: +149.69%
May 9, 2023
Maintains: Overweight
Price Target: $25 → $30
Current: $17.00
Upside: +76.47%
Mar 6, 2023
Maintains: Overweight
Price Target: $6 → $5
Current: $2.31
Upside: +116.45%
Jan 6, 2023
Upgrades: Overweight
Price Target: $10 → $18
Current: $8.25
Upside: +118.18%
May 5, 2022
Maintains: Overweight
Price Target: $104 → $99
Current: $47.59
Upside: +108.03%